Transcranial laser therapy (TLT) using a near-infrared energy laser system was tested in the 2x Tg amyloid precursor
protein (APP) mouse model of Alzheimer's Disease (AD). TLT was administered 3 times/week at escalating doses,
starting at 3 months of age, and was compared to a control group which received no laser treatment. Treatment sessions
were continued for a total of six months. The brains were examined for amyloid plaque burden, Aβ peptides (Aβ1-40 and
Aβ1-42 ), APP cleavage products (sAPPα, CTFβ) and mitochondrial activity. Administration of TLT was associated with
a significant, dose-dependent reduction in amyloid load as indicated by the numbers of Aβ plaques. Levels of Aβ1-40 and
Aβ1-42 levels were likewise reduced in a dose-dependent fashion. All TLT doses produced an increase in brain sAPPα and
a decrease in CTFβ levels consistent with an increase in α-secretase activity and a decrease in β-secretase activity. In
addition, TLT increased ATP levels and oxygen utilization in treated animals suggesting improved mitochondrial
function. These studies suggest that TLT is a potential candidate for treatment of AD.
Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks.
You are receiving this notice because your organization may not have SPIE eBooks access.*
*Shibboleth/Open Athens users─please
sign in
to access your institution's subscriptions.
To obtain this item, you may purchase the complete book in print or electronic format on
SPIE.org.
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.